These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35535988)

  • 1. Dynamics of biosimilar uptake in emerging markets.
    Chhabra H; Mouslim MC; Kashiramka S; Rathore AS
    Expert Opin Biol Ther; 2022 Jun; 22(6):679-688. PubMed ID: 35535988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market.
    Río-Álvarez I; Cruz-Martos E
    Expert Opin Biol Ther; 2024 Jul; 24(7):583-597. PubMed ID: 38842367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Policies for biosimilar uptake in Europe: An overview.
    Moorkens E; Vulto AG; Huys I; Dylst P; Godman B; Keuerleber S; Claus B; Dimitrova M; Petrova G; Sović-Brkičić L; Slabý J; Šebesta R; Laius O; Karr A; Beck M; Martikainen JE; Selke GW; Spillane S; McCullagh L; Trifirò G; Vella Bonanno P; Mack A; Fogele A; Viksna A; Władysiuk M; Mota-Filipe H; Meshkov D; Kalaba M; Mencej Bedrač S; Fürst J; Zara C; Skiöld P; Magnússon E; Simoens S
    PLoS One; 2017; 12(12):e0190147. PubMed ID: 29284064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
    Chen B; Nagai S; Armitage JO; Witherspoon B; Nabhan C; Godwin AC; Yang YT; Kommalapati A; Tella SH; DeAngelis C; Raisch DW; Sartor O; Hrushesky WJ; Ray PS; Yarnold PR; Love BL; Norris LB; Knopf K; Bobolts L; Riente J; Luminari S; Kane RC; Hoque S; Bennett CL
    Oncologist; 2019 Apr; 24(4):537-548. PubMed ID: 30842244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment.
    Mestre-Ferrandiz J; Czech M; Smolen JS; Cornes P; Aapro MS; Danese S; Deitch S; Tyldsley H; Foster W; Shah P; Latymer M; Vulto AG
    Expert Rev Pharmacoecon Outcomes Res; 2024 Apr; 24(4):509-519. PubMed ID: 38284223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key drivers for market penetration of biosimilars in Europe.
    Rémuzat C; Dorey J; Cristeau O; Ionescu D; Radière G; Toumi M
    J Mark Access Health Policy; 2017; 5(1):1272308. PubMed ID: 28265349
    [No Abstract]   [Full Text] [Related]  

  • 7. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.
    Car E; Vulto AG; Houdenhoven MV; Huys I; Simoens S
    Front Pharmacol; 2023; 14():1151764. PubMed ID: 37153785
    [No Abstract]   [Full Text] [Related]  

  • 8. An international comparative analysis and roadmap to sustainable biosimilar markets.
    Alnaqbi KA; Bellanger A; Brill A; Castañeda-Hernández G; Clopés Estela A; Delgado Sánchez O; García-Alfonso P; Gyger P; Heinrich D; Hezard G; Kakehasi A; Koehn C; Mariotte O; Mennini F; Mayra Pérez-Tapia S; Pistollato M; Saada R; Sasaki T; Tambassis G; Thill M; Werutsky G; Wilsdon T; Simoens S
    Front Pharmacol; 2023; 14():1188368. PubMed ID: 37693908
    [No Abstract]   [Full Text] [Related]  

  • 9. Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review.
    Vulto AG; Vanderpuye-Orgle J; van der Graaff M; Simoens SRA; Dagna L; Macaulay R; Majeed B; Lemay J; Hippenmeyer J; Gonzalez-McQuire S
    Pharmaceuticals (Basel); 2020 Nov; 13(11):. PubMed ID: 33213079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases.
    Pentek M; Zrubka Z; Gulacsi L
    Curr Pharm Des; 2017; 23(44):6770-6778. PubMed ID: 29189134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Market diffusion of biosimilars in off-patent biologic drug markets across Europe.
    Böhm AK; Steiner IM; Stargardt T
    Health Policy; 2023 Jun; 132():104818. PubMed ID: 37086662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmarket policy considerations for biosimilar oncology drugs.
    Renwick MJ; Smolina K; Gladstone EJ; Weymann D; Morgan SG
    Lancet Oncol; 2016 Jan; 17(1):e31-8. PubMed ID: 26758759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries.
    Klein K; Gencoglu M; Heisterberg J; Acha V; Stolk P
    BioDrugs; 2023 Mar; 37(2):235-245. PubMed ID: 36472773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023.
    Wu Q; Wang Z; Fu Y; Luo R; Sun J
    Glob Health Res Policy; 2024 Oct; 9(1):42. PubMed ID: 39367503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain.
    Barcina Lacosta T; Vulto AG; Huys I; Simoens S
    Front Med (Lausanne); 2022; 9():1029040. PubMed ID: 36703896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption.
    Barbier L; Simoens S; Vulto AG; Huys I
    BioDrugs; 2020 Dec; 34(6):783-796. PubMed ID: 33141421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting.
    Moorkens E; Simoens S; Troein P; Declerck P; Vulto AG; Huys I
    BioDrugs; 2019 Jun; 33(3):285-297. PubMed ID: 30945207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A health economic guide to market access of biosimilars.
    Simoens S; Vulto AG
    Expert Opin Biol Ther; 2021 Jan; 21(1):9-17. PubMed ID: 33206021
    [No Abstract]   [Full Text] [Related]  

  • 19. Uptake of biosimilar trastuzumab in Denmark compared with other European countries: a comparative study and discussion of factors influencing implementation and uptake of biosimilars.
    Azuz S; Newton M; Bartels D; Poulsen BK
    Eur J Clin Pharmacol; 2021 Oct; 77(10):1495-1501. PubMed ID: 34008071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars in Belgium: a proposal for a more competitive market.
    Moorkens E; Vulto AG; Huys I
    Acta Clin Belg; 2021 Dec; 76(6):441-452. PubMed ID: 32400319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.